Comparison of the sensitivities of three commercial assays for detection of the high risk HPV types 16, 18 and 45

Cuschieri, Kate; Hardie, Alison; Hovland, Siri; Hoaas, Bente; Karlsen, Frank; Cubie, Heather

doi:10.1016/j.jviromet.2013.05.013

Cited by 9 publications

(7 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The studies showed that Proofer was approximately twice as specific as, but 20% less sensitive than, Aptima for CIN2+ detection, which is in line with our results after 36 months of follow up (specificity: 69% vs 34%; sensitivity: 77% vs 94%). Although the 2 mRNA tests both detect E6/E7 mRNA oncoproteins in HPV‐infected cells, the number of HPV types detected by each test differs, which likely explains the differences in test performance . Although Proofer targets only 5 HPV types, which are detected in approximately 75% of CIN2/3 cases, Aptima targets 14 HPV types, which are detected in approximately 90% of CIN2/3 cases …”

Section: Discussionmentioning

confidence: 99%

Triage of low‐grade squamous intraepithelial lesions using human papillomavirus messenger ribonucleic acid tests—A prospective population‐based register study

Reinholdt

Juul

Dehlendorff

et al. 2019

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

Abbreviations: ASCUS, atypical squamous cells of undetermined significance; CI, confidence interval; CIN, cervical intraepithelial neoplasia; CIN2+, cervical intraepithelial neoplasia grade 2 or worse; CIN3+, cervical intraepithelial neoplasia grade 3 or worse; HPV, human papillomavirus; LSIL, low-grade squamous intraepithelial lesions; NPV, negative predictive value; PPV, positive predictive value. AbstractIntroduction: The optimal clinical management of women diagnosed with low-grade squamous intraepithelial lesions (LSIL) during cervical cancer screening remains unclear. In this prospective cohort study, we compared the clinical performance of two human papillomavirus (HPV) mRNA tests for triage of women with LSIL in Denmark. Material and methods:In a nationwide pathology register, we identified women aged 23-65 years with LSIL during 2008-2012. We included women tested for HPV mRNA with the PreTect HPV Proofer test for five high-risk HPV types (n = 2176) or the Aptima assay for 14 high-risk HPV types (n = 426). Subsequent histological diagnoses of cervical intraepithelial neoplasia grades 2, 3 or cancer (CIN2+) were identified in the register. We calculated the sensitivity and specificity for CIN2+ at 18 and 36 months of follow up, and the cumulative incidence of CIN2+ among women testing positive and negative, overall and by age (23-29, 30-39, 40-65 years). Results:The proportion of women with a positive mRNA test at baseline was higher in women tested with Aptima (66.7%) than in women tested with Proofer (42.8%).After 18 months, Aptima had higher sensitivity for CIN2+ than Proofer (98% [95% CI 94% to 100%] vs 85% [95% CI 82% to 88%]), whereas Proofer showed higher specificity than Aptima (67% [95% CI 64% to 70%]) vs (40% [95% CI 33% to 46%]). Aptima had particularly low specificity in women aged <40 years (23-29: 19% [95% CI 5% to 36%]; 30-39: 10% [95% CI 0% to 33%]). The 36-month cumulative incidence of CIN2+ was higher in Proofer positive (54.3% [95% CI 50.9% to 57.8%]) than in Aptima positive women (37.6% [95% CI 31.2% to 44.8%]). In women with a negative mRNA test, the 36-month cumulative incidences of CIN2+ were 13.1% (95% CI 10.8% to 15.8%) and 5.9% (95% CI 1.7% to 19.0%) for Proofer and Aptima, respectively. Conclusions:In women with LSIL, Aptima had high sensitivity for CIN2+, but low specificity, especially in women aged <40 years. The Proofer test may be useful to limit immediate colposcopy referrals in younger women with LSIL, but given its low | 205 REINHOLDT ET aL. S U PP O RTI N G I N FO R M ATI O N Additional supporting information may be found online in the Supporting Information section. How to cite this article: Reinholdt K, Juul KE, Dehlendorff C, Munk C, Kjaer SK, Thomsen LT. Triage of low-grade squamous intraepithelial lesions using human papillomavirus messenger ribonucleic acid tests-A prospective population-based register study. Acta Obstet Gynecol Scand. 2020;99:204-212.

show abstract

Section: Discussionmentioning

confidence: 99%

Triage of low‐grade squamous intraepithelial lesions using human papillomavirus messenger ribonucleic acid tests—A prospective population‐based register study

Reinholdt

Juul

Dehlendorff

et al. 2019

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

show abstract

“…The list of pathogens that can be detected by DNA/RNA-based technology is large, which includes: analysis for the detection of tuberculosis (e.g. Mycobacterium tuberculosis [83]), human papillomavirus (HPV), Chlamydia trachomatis and Neisseria gonorrhoeae [84][85][86][87], avian influenza virus and influenza A (H1N1) virus [88][89], human immunodeficiency virus (HIV) [90,91], measles [92,93], hepatitis A, B, and C [94][95][96][97], among other pathogenic agents.…”

Section: Pathogen Traceability In the Human Body Using Molecular Markersmentioning

confidence: 99%

Predicting Physical Features and Diseases by DNA Analysis: Current Advances and Future Challenges

Cerqueira¹,

Ramallo²,

Hünemeier³

et al. 2016

J Forensic Res

View full text Add to dashboard Cite

The 'omics' era and its concomitant technological advances have brought great insight into genetics. One of the most promising fields within human genetics is the prediction of physical traits from analysis of genetic material. Besides the predictive potential of DNA, the traceability of pathogenic agents in the human body through molecular analysis is also a field to be further exploited. In this review, we aim to discuss specific aspects of phenotypic prediction by analysing DNA, with special emphasis on normal variation, and the application of a technology known as 'Forensic DNA Phenotyping' (FDP). We also suggest the term 'Phenotype Informative Markers' (PIMs) to designate any molecular markers responsible for normal or pathological human phenotypic variation. In addition, we raise some recommendations related to forensic genetics, the molecular diagnosis of human diseases, and the traceability of pathogens in the human body, giving special emphasis to the need for validation of these tests with strict protocols. Some relevant concerns about privacy, ethics, and legality of such predictions have also been discussed. Finally, we look at perspectives on the use of epigenetic tools, and quote some examples of what has been done in this specific field.

show abstract

“…In clinical testing for HPV, DNA or mRNA is usually extracted from the cervical specimen first. After amplification by PCR with specific primers, the presence of the HPV sequence can be identified by a probe to determine whether the sample is infected with HPV . There are approximately 200 HPV genotypes .…”

Section: Introductionmentioning

confidence: 99%

Rapid detection of low‐level HeLa cell contamination in cell culture using nested PCR

Lin

Jiang

et al. 2018

J Cellular Molecular Medi

View full text Add to dashboard Cite

HeLa cells are a commonly used cell line in many biological research areas. They are not picky for culture medium and proliferate rapidly. HeLa cells are a notorious source of cell cross‐contamination and have been found to be able to contaminate a wide range of cell lines in cell culture. In this study, we reported a simple and efficient method for detecting the presence of HeLa cell contamination in cell culture. HPV‐18 was used as a biomarker. The cell culture supernatant was used directly as the template for nested PCR without extracting nucleic acid. By PCR amplification of the cell culture supernatant with the designed primers, we were able to detect the presence of HeLa cells in the culture. The sensitivity of this method can reach 1%, which is 10‐fold higher than Short tandem repeat sequence (STR) profiling. This simple, rapid, and “noninvasive” quality checking method should find applications in routine cell culture practice.

show abstract

Comparison of the sensitivities of three commercial assays for detection of the high risk HPV types 16, 18 and 45

Cited by 9 publications

References 14 publications

Triage of low‐grade squamous intraepithelial lesions using human papillomavirus messenger ribonucleic acid tests—A prospective population‐based register study

Triage of low‐grade squamous intraepithelial lesions using human papillomavirus messenger ribonucleic acid tests—A prospective population‐based register study

Predicting Physical Features and Diseases by DNA Analysis: Current Advances and Future Challenges

Rapid detection of low‐level HeLa cell contamination in cell culture using nested PCR

Contact Info

Product

Resources

About